Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

NEUROPAIN

financed

Closed

Neuropathic pain biomarkers and druggable targets within the endogenous analges...

Neuropathic pain biomarkers and druggable targets within the endogenous analgesia system Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patie... see more

31/12/2018

UPF

9M€

Project Budget: 9M€

Project leader

UNIVERSITAT POMPEU FABRA No se ha especificado una descripción o un objeto social para esta compañía.

total researchers 324

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 12 Participantes

Financing granted El organismo FP7 notifico la concesión del proyecto The day 2018-12-31 We do not have the information of the call

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

UPF

0.00€ | Leader

CHARITE UNIVERSITAETSMEDIZI...

N.D. | participant

UNIVERSITY COLLEGE LONDON

ESTEVE PHARMACEUTICALS

N.D. | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

UNIVERSITAT POMPEU FABRA No se ha especificado una descripción o un objeto social para esta compañía.

total researchers 324

Project Budget 9M€

participation deadline Sin fecha límite de participación.

Project description Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous investment by the pharmaceutical industry. Important reasons for this failure are the poor predictive validity of currently available animal models of chronic pain, that do not simulate multidimensional clinical pain, and the high inter-individual variability of neuropathic pain manifestations and treatment responses. We will overcome these obstacles by an interdisciplinary collaboration between basic science groups, clinicians and leading private companies. This consortium will validate new animal models to evaluate the electrophysiological, behavioural, emotional and cognitive manifestations of neuropathic pain and the effectiveness of novel compounds. The use of these models in combination with other behavioural paradigms and new conditional knockout mouse lines for specific components of the endogenous opioid and cannabinoid system will permit the identification of novel druggable targets and biomarkers for neuropathic pain. Novel analgesic compounds acting on these endogenous systems developed by the private companies of the consortium will be tested in these new paradigms. Clinical studies will identify novel biomarkers for neuropathic pain using powerful genetics approaches and investigate treatment effectiveness with a translational focus based on cross validation of the findings in animals and humans.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers